SILVER SPRING, Maryland — The US Food and Drug Administration (FDA) has launched a program that allows drug companies to share the agency’s detailed scientific and regulatory reviews with health regulators in other countries, in a move the agency says could speed up patient access to new medicines worldwide.
Under the Global Reliance Disclosure Program, announced on 17 November, the FDA will provide companies with minimally redacted copies of its approval packages, which they can pass to foreign regulators assessing the same product. The program began on 30 October with a tentative approval of the HIV medicine lenacapavir under the US President’s Emergency Plan for AIDS Relief (PEPFAR), and the FDA plans to extend it to all novel drugs and biologics in January 2027.

How the program works
When the FDA approves a medicine, its reviewers produce detailed assessments of the clinical trial data, manufacturing quality, safety and the reasons for the decision. Until now, regulators in other countries could not easily see these documents in full, so many repeated large parts of the evaluation themselves.
Under the new program, an eligible company can request its approval package within 10 calendar days of approval and must confirm that the package is going to a foreign regulatory authority. The FDA will share the package with only minimal non-public information removed, and says it intends to provide packages on an expedited basis. Eligible companies will be told about the option in their approval letters.
The foreign regulator can then rely on the FDA’s review instead of repeating a full evaluation, while keeping control over its own decision. Requests for approval documents for other purposes, such as academic research, are not handled through the program and must go through the US Freedom of Information Act process.
Starting with HIV medicines
The program currently covers tentative approvals granted under PEPFAR, a scheme that allows the FDA to review medicines, including generic versions, for purchase through the US global HIV program even when patents or exclusivity prevent their sale in the United States. Tentatively approved abbreviated new drug applications are excluded.
The first package was shared for lenacapavir, a long-acting HIV medicine given by injection twice a year that has been approved in the United States for HIV prevention and treatment. Public health agencies and advocates have pressed for rapid access to lenacapavir in countries with high HIV burdens, and faster regulatory decisions in those countries are seen as an important step.
Planned expansion in 2027
The FDA said it plans to expand the program in January 2027 to novel drugs and biologics, specifically new molecular entity applications and biologics licence applications. It also plans to introduce, in early 2027, a pathway for companies to request packages for drugs and biologics already on the market.
On its website, the FDA said the program “fundamentally transforms how the FDA’s regulatory drug and biologic approval decisions are leveraged by health authorities around the world and may accelerate patient access to innovative therapies.” The agency did not name specific foreign regulators that would take part. Some media reports have noted interest from regulators in Asia, but the FDA has not confirmed participating countries.
Why reliance matters
Regulatory reliance, in which one regulator takes into account the work of another trusted regulator, has become a central strategy for speeding up access to medicines, particularly in low- and middle-income countries with limited regulatory capacity. The World Health Organization has published good reliance practices and encourages regulators to share work rather than duplicate it.
Medicines can reach patients in some countries years after they are approved in the United States or Europe, partly because each regulator conducts its own review. Reliance pathways aim to shorten these delays without lowering standards, by allowing national regulators to focus their resources on questions specific to their populations, such as local disease patterns, supply chains and labelling.
The FDA has previously supported reliance through confidentiality agreements with other regulators and through initiatives such as Project Orbis, which allows cancer medicines to be reviewed jointly by several regulators. The new program differs by giving companies documents they can submit directly as part of applications abroad.
What happens next
Companies with eligible products will receive details in FDA approval letters. Regulatory affairs teams at companies developing novel drugs and biologics have been advised to prepare procedures for requesting packages within the 10-day window once the program expands in January 2027.
How much the program speeds up access will depend on how many foreign regulators choose to rely on FDA reviews, and on whether they can process applications quickly once they receive the packages.
Key facts at a glance
- The FDA announced the Global Reliance Disclosure Program on 17 November 2026.
- The program began on 30 October 2026.
- Its first use was a PEPFAR tentative approval for lenacapavir.
- Companies can share minimally redacted FDA approval packages with foreign regulators.
- Requests must be made within 10 calendar days of approval.
- Foreign regulators keep control of their own decisions.
- The program will expand to novel drugs and biologics in January 2027.
- A pathway for already marketed products is planned for early 2027.
- Other requests for documents must go through Freedom of Information Act procedures.
- Reliance aims to cut duplication and speed patient access worldwide.
What is in an FDA approval package?
An approval package typically includes the reviews written by FDA scientists and clinicians across different disciplines: clinical, statistical, pharmacology and toxicology, chemistry and manufacturing, and clinical pharmacology. It summarises the evidence from trials, identifies safety concerns, explains how the agency weighed benefits and risks, and sets out conditions such as warnings, required studies after approval or risk management plans.
For a regulator with limited staff, receiving such a package can save months of work. Instead of reviewing all raw data from the beginning, it can examine the FDA’s conclusions, check whether they apply to its own population, and focus its expertise on local issues. This is especially valuable for medicines for HIV, tuberculosis, malaria and other diseases with a heavy burden in low- and middle-income countries.
What lenacapavir is
Lenacapavir is a long-acting medicine that blocks the HIV capsid, a protein shell that protects the virus’s genetic material. For prevention, it is given as an injection under the skin twice a year, which removes the need for daily pills. Clinical trials showed very high levels of protection against HIV infection in people who received it.
Global health agencies see twice-yearly prevention as a potential turning point in the HIV response, because daily pills can be hard for some people to take consistently. Programmes to supply lenacapavir to countries with high HIV burdens at reduced cost have been announced, and rapid national regulatory approval is one of the steps needed before it can be used.
Background: PEPFAR and tentative approvals
PEPFAR, launched by the United States in 2003, is the largest commitment by any country to address a single disease. It has funded HIV testing, treatment and prevention in dozens of countries, particularly in sub-Saharan Africa, and is credited with saving millions of lives.
To allow PEPFAR to buy lower-cost medicines while ensuring their quality, the FDA created a review process in 2004 for HIV medicines intended for the program, including generic and fixed-dose combination products made outside the United States. When a product meets FDA standards but cannot be sold in the United States because of patents or market exclusivity, the FDA grants a tentative approval, which allows it to be purchased for use abroad.
Many countries that receive PEPFAR-funded medicines must still register them with their own regulators before they can be used. Sharing the FDA’s detailed reviews of these products is intended to shorten that national step, so that medicines purchased for HIV programmes can reach clinics sooner.
The FDA’s broader shift towards reliance also reflects a recognition that regulators around the world face growing workloads as the number of complex medicines, including biologics and cell and gene therapies, increases. Sharing assessments is one way to use limited regulatory expertise more efficiently.
What this means for patients and families
For patients, the main potential benefit is faster access to new medicines outside the United States. When national regulators can rely on detailed FDA reviews, they may approve important treatments sooner, reducing the gap between approval in wealthy countries and availability elsewhere.
Patients should continue to use medicines only as approved and prescribed in their own country. Reliance does not mean a medicine approved in the United States is automatically available or approved elsewhere; each country still makes its own decision.
Patient groups in many countries have long campaigned for faster approval of new treatments, particularly for HIV, cancer and rare diseases. People who want to know whether a medicine is available locally can ask their nurse, pharmacist or healthcare provider, or check the website of their national medicines regulator, which usually publishes lists of approved products.
What it means for nurses
Nurses working in HIV, oncology, infectious diseases and other specialties may see new medicines arrive in their countries sooner if regulators take up the program. That makes it important to stay informed about national approvals, updated treatment guidelines and new training needs, such as administering long-acting injectable medicines.
Nurses in regulatory, pharmacovigilance and research roles can also contribute, by reporting suspected side effects and supporting post-approval monitoring, which remains a national responsibility even when approvals rely on another regulator’s review.
Questions and answers
What is the Global Reliance Disclosure Program?
An FDA program that lets companies share minimally redacted FDA approval reviews with foreign regulators.
Which medicines are covered now?
Currently PEPFAR tentative approvals, starting with lenacapavir. Novel drugs and biologics will be added in January 2027.
Do foreign regulators have to accept FDA decisions?
No. They keep full control of their own decisions and can use the FDA’s review as they see fit.
Can the public see these packages?
Not through this program. Other requests must go through the Freedom of Information Act.
Why does this matter for global health?
It could reduce duplicated reviews and speed up access to new medicines in countries with limited regulatory capacity.
How we reported this story
Nursing Media Network reports health news for an international audience. This report is based on official statements, surveillance data and published research, which are linked in the sources below. Figures are given as they stood on the date of publication and may change as authorities release new data. Where officials or researchers are quoted, their words are taken from their published statements.
This article is for information and does not replace advice from a nurse or healthcare provider who knows your situation. If you have symptoms or questions about your own health, contact your local health service.
Finding reliable health information
Health information online varies widely in quality. Prefer sources such as the World Health Organization, national health ministries, public health agencies, university hospitals and registered professional bodies. Be cautious with social media posts, miracle cures and products sold with promises that sound too good to be true.
If you read something that worries you or contradicts the advice you have been given, write it down and discuss it with your nurse or healthcare provider. They can explain how it applies to your own situation and help you separate evidence from rumour.
Questions to ask your nurse or healthcare provider
- Is this new medicine approved in my country?
- When might a newly approved medicine become available here?
- Is long-acting HIV prevention available where I live?
- Where can I report side effects of a new medicine?
- How do I stay updated on new treatment guidelines?
But doesn’t relying on the FDA weaken national regulators?
Not necessarily. Reliance lets regulators focus on local questions while keeping the final decision. WHO encourages such work-sharing as long as regulators retain their independence.
Your next step: If you work with HIV or other priority medicines, follow your national regulator’s announcements so you know when new treatments are approved locally.
Related: New FDA approvals for Niemann-Pick and Gaucher disease · Pandemic Agreement · Hormone-disrupting chemicals report
Sources: FDA press announcement; CASRAI; Pharmaceutical Commerce; FDA.



Leave a Reply